Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.

This descriptive analysis examines malignancy events reported among guselkumab-treated patients with prior malignancy (excluding NMSC) during VOYAGE 1 and VOYAGE 2 (NCT02207231; NCT02207244). More patients across a broader range of time following cancer remission and longer duration of follow-up are needed to better characterize the safety of guselkumab in patients with prior malignancy. Https://doi.org/10.1093/bjd/ljad081 Dear Editor, The pivotal 5-year VOYAGE 1 and 2 studies of guselkumab in moderate-to-severe psoriasis[1],[2] are among the first studies of biologics to include patients with a history of malignancy, including treated nonmelanoma skin cancer (NMSC) or cervical cancer I in situ i (without evidence of recurrence for >= 3 months) or other malignancy > 5 years before enrolment. [Extracted from the article]